** Shares of Zevra Therapeutics ZVRA.O rise 5.14% to $7.77
** Zevra says it enters agreement to sell its rare pediatric disease Priority Review Voucher $(PRV.UK)$ for $150 million
** The U.S. FDA granted the company PRV in September 2024 after approval of its drug Miplyffa
** Miplyffa is indicated for use in combination with co's other genetic disorder drug, miglustat, to treat rare neurological condition passed genetically in adult and pediatric patients 2 years of age and older
** PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA
** ZVRA has fallen 7.19% YTD
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。